September, 3 2015 – Santen UK Limited (St Albans, UK) has today announced the successful marketing authorization transfer of MSD's (known as Merck & Co., Inc., Kenilworth, NJ, USA, in the US and Canada) ophthalmology product range COSOPT®, COSOPT® Preservative‑Free, SAFLUTAN®, TIMOPTOL®, TRUSOPT® and TRUSOPT® Preservative‑Free. The Marketing authorisations were successfully transferred from MSD to Santen on 31 July 2015.
Santen has over 120 years dedicated to ophthalmology, and is the largest Japanese ophthalmology company. Santen's priority is to develop and acquire new and better solutions that respond to the needs of both patients and healthcare professionals in main therapeutic areas, focussing on Glaucoma and Dry Eye.
Santen is committed to delivering high quality innovative treatments with a safety profile that puts patients first at every step of the process. COSOPT®, COSOPT® Preservative‑Free, SAFLUTAN®, TIMOPTOL®, TRUSOPT® and TRUSOPT® Preservative‑Free complement Santen's existing portfolio of ophthalmology treatments for glaucoma and dry eye disease. This acquisition marks a significant step in Santen's ambition to build a market-leading ophthalmology franchise of innovative products for unmet medical needs to improve patients' quality of life.
During the transition of these products from MSD to Santen, Santen's priority is to ensuring continuity of supply of its medicines to patients and healthcare professionals. To this end, healthcare professionals are asked to note the following:
Santen has appointed United Drug Distributors as their distributor in Ireland for COSOPT®, COSOPT® Preservative‑Free, SAFLUTAN®, TIMOPTOL®, TRUSOPT® and TRUSOPT® Preservative‑Free – orders can now be placed with your local wholesaler;
There are currently good levels of stock for all Santen ophthalmology products across the Republic of Ireland;
Before the end of 2015, healthcare professionals and patients can expect to see the packaging of these products updated to carry the Santen logo instead of the MSD logo. No other changes are being made to the product. When Santen-branded product is about to enter the supply chain, Santen will notify hospital and retail pharmacists to alert them to the new Santen-branded packaging.
For medical information queries about any of Santen's products, contact Santen Medical Information on +353 1 695 0008 or firstname.lastname@example.org. For all other queries, contact Santen on +44 1727 884523 or email@example.com.
COSOPT® SmPC, available at: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1286-006-001_31072015142315.pdf
COSOPT® Preservative‑Free SmPC, available at: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0879-005-002_21082015121108.pdf
SAFLUTAN® SmPC, available at: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1286-041-001_31072015142257.pdf
TIMOPTOL® 0.25% SmPC, available at: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1286-020-001_31072015143352.pdf
TIMOPTOL® 0.5% SmPC, available at: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1286-020-002_31072015143344.pdf
TRUSOPT® SmPC, available at: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1286-021-001_31072015142329.pdf
TRUSOPT® SmPC, available at: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1286-021-002_31072015142321.pdf
As a specialty company dedicated to the ophthalmic and anti-rheumatic fields, Santen carries out the research, development, sales, and marketing of pharmaceuticals. The company has its bases in about 20 countries and delivers products in more than 70 countries. In Japan, Santen holds the No. 1 share in the prescription ophthalmic pharmaceutical market. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.
Information provided in this press release contains so-called "Forward-Looking Statements". The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of change in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
NewCap Media Relations
Tel: +33 1 44 71 94 98
Corporate Communication Director - Santen Europe
Tel: +33 1 42 17 49 50
General Manager UK & Ireland
Tel: +44 1727 884523